Skip to main content

TCG Crossover — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

81
Companies
$14.3B
Total invested
$176.4M
Avg. check
10
Industries
Biotechnology 22Therapeutics 18Health Care 12Medical 11Pharmaceutical 10Biopharma 7+4 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 81
Aclaris Therapeutics
October 2026

Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.

Biotechnology · Wayne$50.0M Post-IPO Equity
Disc Medicine
October 2026

Disc Medicine is a biopharmaceutical company that develops therapies for hematologic diseases and rare blood disorders.

Biotechnology · Watertown$450.0M Post-IPO Equity
Alector
October 2026

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

Biotechnology · South San Francisco$50.0M Post-IPO Equity
Soufflé Therapeutics
October 2026

Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.

Biopharma · Boston$135.0M Series B
ADC Therapeutics
October 2026

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

Biopharma · Lausanne$86.6M Post-IPO Equity
TriGemX Bio
October 2026

TriGemX Bio uses the science of gut-brain biology to create medicines that transform human health.

Biotechnology · New York$94.0M Venture - Series Unknown
AN2 Therapeutics
September 2026

AN2 Therapeutics develops small-molecule medicines from boron chemistry for infectious diseases, hematologic disorders, and oncology.

Biotechnology · Menlo Park$40.0M Grant
Tyra Biosciences
September 2026

Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.

Biotechnology · Carlsbad$400.0M Post-IPO Equity
Vaderis Therapeutics
August 2026

Vaderis Therapeutics is a clinical-stage biotechnology company developing targeted therapies for rare vascular diseases.

Biotechnology · Basel$152.0M Series B
LB Pharmaceuticals
July 2026

LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.

Biopharma · New York$150.0M Post-IPO Equity
Ollin Biosciences
June 2026

Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases.

Biopharma · Austin$330.0M Series B
Mineralys Therapeutics
June 2026

Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.

Biopharma · Radnor$500.0M Post-IPO Debt
Mirum Pharmaceuticals
May 2026

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.

Biotechnology · Foster City$600.0M Post-IPO Debt
Abivax
May 2026

Abivax develops medicines that alter the body's natural immune system mechanisms.

Biotechnology · Paris$45.0M Post-IPO Equity
Avalo Therapeutics
May 2026

Avalo Therapeutics is a clinical-stage biopharmaceutical company.

Biotechnology · Rockville$431.3M Post-IPO Equity
Valneva
April 2026

Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.

Biotechnology · Saint-herblain$43.1M Post-IPO Equity
Maze Therapeutics
April 2026

Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.

Biopharma · South San Francisco$150.0M Post-IPO Equity
ADCendo
April 2026

Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.

Biotechnology · Copenhagen$75.0M Series C
Vor Biopharma
March 2026

Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.

Biotechnology · Cambridge$75.0M Post-IPO Equity
Inhibrx
March 2026

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.

Biopharma · La Jolla$75.0M Post-IPO Debt
Immunic Therapeutics
February 2026

Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.

Biotechnology · New York$400.0M Post-IPO Equity
Perspective Therapeutics
February 2026

Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.

Health Care · Seattle$175.0M Post-IPO Equity
Century Therapeutics
January 2026

Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.

Biotechnology · Philadelphia$135.0M Post-IPO Equity
Beacon Therapeutics
January 2026

Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.

Biotechnology · Alachua$75.0M Series C

Where TCG Crossover invests

Biotechnology22
Therapeutics18
Health Care12
Medical11
Pharmaceutical10
Biopharma7

About TCG Crossover's portfolio

How many companies has TCG Crossover invested in?▸

TCG Crossover has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does TCG Crossover invest in?▸

TCG Crossover's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Pharmaceutical. The firm invests across 10 different industry categories.

What is TCG Crossover's largest investment?▸

Among tracked funding rounds, Mirum Pharmaceuticals received $600.0M in a Post-IPO Debt round. TCG Crossover's total known invested capital is $14.3B.

What is the average investment size for TCG Crossover?▸

TCG Crossover's average investment size is $176.4M across its portfolio of 81 companies.

What are TCG Crossover's most recent investments?▸

Recent TCG Crossover portfolio additions include Aclaris Therapeutics, Disc Medicine, Alector, Soufflé Therapeutics, ADC Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 81 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →